| CAS NO: | 860033-06-3 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 860033-06-3 |
| Canonical SMILES | O=C(O)C[C@@H]1CCN2C1=C(SC3=CC=C(Cl)C=C3)C4=C2C=C(F)C=C4 |
| 分子式 | C19H15ClFNO2S |
| 分子量 | 375.84 |
| 溶解度 | DMSO : ≥ 150 mg/mL (399.11 mM);Water :< 0.1 mg/mL (insoluble) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | L 888607 is a potent, and selective CRTH2 (also known as DP2) agonist with a Ki of 0.8±0.4 nM. L 888607 (L-888,607) is administered to mice either intravenously (i.v.) or orally (p.o.) to determine its pharmacokinetic profile over an 8-h period. After an intravenous administration of 5 mg/kg L 888607, blood analysis reveals a peak level (Cmax) of 36.1 μM, a half-life (t1/2) of 2.9 h, a trough level at 8 h (C8h) of 3.5 μM, and an area under the curve0-8h of 87.1 μM. After oral administration of 20 mg/kg L 888607, blood analysis reveals a Cmax of 31.6 μM, a t1/2 of 4 h, a C8h at 8 h of 15.4 μM, an area under the curve0-8h of 166 μM, and a bioavailability of 48%[1]. [1]. Gervais FG, Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol. 2005 Jun;67(6):1834-9. [2]. Ulven T, et al. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin Ther Pat. 2010 Nov;20(11):1505-30. |
m.cnreagent.com